Differentiating NMOSD and MOGAD in Real-World Cohorts

Differentiating NMOSD and MOGAD represents a vital priority in modern neuroimmunology. Both conditions involve severe central nervous system demyelination. However, their underlying pathogenesis and clinical courses diverge significantly. Historically, clinicians frequently misclassified these disorders as multiple sclerosis. Consequently, many patients received inappropriate immunomodulatory treatments. The discovery of aquaporin-4 autoantibodies revolutionized diagnostic paradigms. Subsequently, identification of myelin oligodendrocyte glycoprotein antibodies established MOGAD as an autonomous disease entity.

Recent data from the Italian Multiple Sclerosis and Related Disorders Registry provide invaluable real-world evidence. This multicenter analysis evaluated 664 patients across 97 specialized centers. Specifically, the cohort comprised 406 individuals with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and 258 individuals with MOGAD. Therefore, this dataset offers one of the largest real-world comparative assessments available today. Understanding how these cohorts diverge demographically and therapeutically informs routine clinical practice. Furthermore, accurate differentiation prevents therapeutic failure and reduces accumulated disability. As targeted immunotherapies expand rapidly, identifying optimal regimens becomes essential for frontline physicians. In addition, distinguishing disease trajectories early ensures timely access to specialized monoclonal antibody therapies and prevents permanent disability.

Demographic and Distinct Clinical Phenotypes

Demographic characteristics reveal pronounced differences between both autoimmune cohorts. In the registry cohort, female sex predominated overwhelmingly among patients with aquaporin-4 positive disease. In contrast, patients with MOGAD exhibited a far more balanced gender distribution. Furthermore, age at clinical onset differed markedly across the two patient groups. Patients with MOGAD generally presented at a younger age. Conversely, aquaporin-4 positive disease typically manifested in middle-aged adults.

Clinical presentation at attack onset also showed clear divergences. Aquaporin-4 positive individuals frequently presented with severe longitudinally extensive transverse myelitis. Moreover, intractable nausea, vomiting, and hiccoughs marked area postrema syndrome in this group. In contrast, individuals with MOGAD frequently developed bilateral optic neuritis or acute disseminated encephalomyelitis-like episodes. Consequently, initial neurological deficits varied considerably between cohorts. Nevertheless, acute relapses caused significant functional morbidity in both populations. Recognizing these distinguishing clinical features allows physicians to initiate targeted diagnostic antibody testing promptly. Thus, detailed clinical phenotyping remains the foundation for rapid and accurate therapeutic intervention. Early recognition also prevents the catastrophic administration of MS-specific disease-modifying therapies.

Comparing Relapse Patterns and Disability Trajectories

Disability accrual follows profoundly distinct trajectories in these two demyelinating conditions. Aquaporin-4 positive disease behaves as an aggressively relapsing condition where neurological recovery remains notoriously poor. Therefore, every single attack leaves cumulative, permanent motor and visual deficits. In contrast, patients with MOGAD frequently experience better functional recovery following acute inflammatory attacks. However, recurrent relapses in MOGAD still produce substantial cumulative visual impairment and physical disability over time.

Registry findings emphasize that time to first relapse serves as a vital prognostic marker. Without effective maintenance therapy, patients face high relapse rates within twelve to twenty-four months. Furthermore, secondary progressive courses rarely occur in either disorder. Instead, disability accumulates almost exclusively through attack-related injury. Consequently, preventing future relapses is the supreme objective of long-term neuroimmunological care. Effective disease management requires early stratification based on relapse risk. Moreover, physicians must recognize that incomplete recovery after the index attack indicates high vulnerability. Therefore, continuous clinical and radiological vigilance remains essential during follow-up. Prompt escalation limits cumulative axonal damage over time.

Rituximab Response Predictors in NMOSD and MOGAD Management

Evaluating treatment response across therapeutic classes provides decisive guidance for preventive management. The registry analysis demonstrated that monoclonal antibodies significantly prolonged the time to first relapse compared to conventional oral immunosuppressants. Specifically, rituximab demonstrated superior relapse-prevention efficacy over azathioprine and mycophenolate mofetil. Therefore, B-cell depletion remains a cornerstone of relapsing demyelinating disease management. However, clinical response to rituximab varied according to antibody status and baseline patient factors.

Multivariable logistic regression identified critical predictors of relapse-free status under rituximab therapy. Notably, earlier initiation of rituximab after symptom onset predicted sustained remission. Furthermore, lower pre-treatment attack frequency and younger age correlated with favorable therapeutic outcomes. In contrast, delayed treatment initiation and high baseline disability significantly diminished the likelihood of remaining relapse-free. In addition, serological persistence of high antibody titers influenced relapse susceptibility. Consequently, these findings highlight the need for rapid escalation to monoclonal antibodies rather than prolonged trials of conventional oral agents. Clinicians should therefore optimize monitoring protocols to detect early subclinical disease activity.

Clinical Implications and Maintenance Strategies in Indian Practice

The findings from large registries provide crucial insights for clinical practice in India. In Indian cohorts, neuromyelitis optica spectrum disorders represent a substantial proportion of non-MS demyelinating central nervous system conditions. Furthermore, resource constraints often restrict access to expensive newer biologics such as satralizumab, inebilizumab, and eculizumab. Therefore, rituximab remains the most accessible and widely utilized monoclonal antibody across tertiary centers in India. However, achieving sustained remissions requires meticulous attention to infusion schedules and immunological monitoring.

Clinicians should implement structured monitoring using CD19 and CD20 B-cell counts to guide redosing intervals. Furthermore, routine screening for latent infections, including tuberculosis and hepatitis B, is mandatory before starting rituximab in Indian settings. Because relapses carry devastating risks of permanent paraplegia or blindness, waiting for treatment failure on oral immunosuppressants is dangerous. Moreover, long-term oral corticosteroid tapering must be managed cautiously to avoid rebound attacks. Thus, adopting risk-stratified, proactive treatment algorithms protects long-term neurological function. Multidisciplinary collaboration among neurologists, ophthalmologists, and rehabilitation specialists ensures comprehensive patient support.

How do clinical phenotypes differ between AQP4-positive NMOSD and MOGAD?

AQP4-positive disease occurs predominantly in adult females and presents with longitudinally extensive transverse myelitis or intractable area postrema syndrome, often causing severe permanent disability. In contrast, MOGAD demonstrates a balanced sex distribution, younger onset, frequent bilateral optic neuritis, and typically superior functional recovery following acute demyelinating attacks.

Why is rituximab considered superior to conventional oral immunosuppressants?

Registry data show that monoclonal antibodies like rituximab significantly prolong time to first relapse compared to conventional agents such as azathioprine or mycophenolate mofetil. Rituximab achieves rapid, targeted B-cell depletion, which directly interrupts pathogenic autoantibody production, reduces attack frequency, and prevents cumulative, attack-related neurological disability.

What baseline factors predict a relapse-free status on rituximab therapy?

Multivariable regression indicates that early rituximab initiation after symptom onset and lower baseline attack frequency strongly predict relapse-free status. Conversely, older age, delayed therapeutic initiation, and higher accumulated neurological disability prior to treatment correlate with higher risks of breakthrough relapses during maintenance B-cell depletion.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Tortorella C et al. Clinical phenotype and treatment response in AQP4-IgG-positive NMOSD and MOGAD: insights from the Italian I-MS&RD registry. J Neurol. 2026 Oct 16. doi: 10.1007/s00415-026-14185-2. PMID: 42881253.


2. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282.


3. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.